Richard M Trosch1, Alberto J Espay2, Daniel Truong3, Ramon Gil4, Carlos Singer5, Peter A LeWitt6, Mark F Lew7, Michele Tagliati8, Charles H Adler9, Jack J Chen10, Dominic Marchese11, Cynthia L Comella12. 1. Oakland University William Beaumont School of Medicine, 32255 Northwestern Highway, Suite 40, Farmington Hills, MI 48334, United States. Electronic address: richardtrosch@comcast.net. 2. Department of Neurology, UC Neuroscience Institute, University of Cincinnati, 260 Stetson Street, Cincinnati, OH 45267, United States. Electronic address: espayaj@ucmail.uc.edu. 3. The Parkinson's and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, United States. Electronic address: dtruong@pmdi.org. 4. Parkinson's Disease Treatment Center of Southwest Florida, 4235 King Highway, Port Charlotte, FL 33980, United States. Electronic address: drgil@parkinsonsfl.com. 5. Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Miami, Leonard M. Miller School of Medicine, 1150 NW 14th Street, Miami, FL 33136, United States. Electronic address: csinger@med.miami.edu. 6. Parkinson's Disease and Movement Disorders Program, Henry Ford Hospital, Wayne State University School of Medicine, 6777 W Maple Road, West Bloomfield, MI 48322, United States. Electronic address: plewitt1@hfhs.org. 7. Division of Movement Disorders, Department of Neurology, University of Southern California, Keck School of Medicine, 1520 San Pablo Street #3000, Los Angeles, CA 90033, United States. Electronic address: mark.lew@med.usc.edu. 8. Department of Neurology, Cedars-Sinai Medical Center, 8631 W 3rd St #215e, Los Angeles, CA 90048, United States. Electronic address: michele.tagliati@cshs.org. 9. Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, United States. Electronic address: cadler@mayo.edu. 10. College of Pharmacy, Marshall B. Ketchum University, 2575 Yorba Linda Blvd, Fullerton, CA 92831, United States. Electronic address: jchen@ketchum.edu. 11. Ipsen Biopharmaceuticals, Inc., 106 Allen Rd, Basking Ridge, NJ 07920, United States. Electronic address: dominic.marchese@ipsen.com. 12. Department of Neurological Sciences, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, United States. Electronic address: ccomella@rush.edu.
Abstract
BACKGROUND: The ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice. METHODS: Adults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction≥25% and Patient Global Impression of Change [PGIC] score of +2 or +3 at Week 4 of Cycle 1). RESULTS: 350 patients enrolled (75% women; mean age 59±13.6years; 27.4% botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6% (n=304) and the TWSTRS total score decreased 27.4% from baseline. PGIC of at least "Much improved" was documented in 43.6% of patients and maintained in Cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5%); the most common were dysphagia (n=6), muscle weakness (n=4), and neck pain (n=3). CONCLUSION: This study confirmed the beneficial effect of abobotulinumtoxinA on CD in routine clinical practice as measured by improvements in TWSTRS and PGIC. No new safety concerns were identified.
BACKGROUND: The ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice. METHODS: Adults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction≥25% and Patient Global Impression of Change [PGIC] score of +2 or +3 at Week 4 of Cycle 1). RESULTS: 350 patients enrolled (75% women; mean age 59±13.6years; 27.4% botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6% (n=304) and the TWSTRS total score decreased 27.4% from baseline. PGIC of at least "Much improved" was documented in 43.6% of patients and maintained in Cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5%); the most common were dysphagia (n=6), muscle weakness (n=4), and neck pain (n=3). CONCLUSION: This study confirmed the beneficial effect of abobotulinumtoxinA on CD in routine clinical practice as measured by improvements in TWSTRS and PGIC. No new safety concerns were identified.
Authors: Vijay P Misra; Carlo Colosimo; David Charles; Tae Mo Chung; Pascal Maisonobe; Savary Om Journal: J Neurol Date: 2017-12-21 Impact factor: 4.849
Authors: Joseph Jankovic; Daniel Truong; Atul T Patel; Allison Brashear; Marian Evatt; Roman G Rubio; Chad K Oh; Daniel Snyder; Gill Shears; Cynthia Comella Journal: Mov Disord Clin Pract Date: 2018-04-26